Nexcella Announces 50 Patients Already Treated with CAR-T NXC-201; Estimates 100-Patient Total Enrollment for U.S. Food and Drug Administration Approval BLA Submission

Nexcella, Inc. announced 50 relapsed/refractory multiple myeloma patients had already been dosed with next-generation CAR-T NXC-201 in its ongoing Phase Ib/IIa clinical trial. Nexcella anticipated 100-patient open-label total enrollment to seek US FDA BLA approval.